(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Before trips to Mars, we need better protection from cosmic rays - 2Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026
- 3Most loved Web-based feature: Which Stage Do You Like
- 4Where America’s CO2 emissions come from – what you need to know, in charts
- 5NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
- False fuel prices in fabricated graphics circulate in Malaysia as Iran war continues
- Four countries to boycott Eurovision 2026 over Israel’s inclusion
- Phenomenal Web-based MBA Stages for Proficient Headway
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- New Jordan security fence could be done in early 2028
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- After fleeing past Hezbollah fighting, some Israelis on northern border vow to stay
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Polar bears are rewiring their own genetics to survive a warming climate
